journal
MENU ▼
Read by QxMD icon Read
search

Ecancermedicalscience

journal
https://www.readbyqxmd.com/read/28101141/the-principles-of-cancer-staging
#1
EDITORIAL
James Brierley, Mary Gospodarowicz, Brian O'Sullivan
The anatomic disease extent or tumour stage of a cancer at diagnosis as a determinant of prognosis is discussed. The importance of cancer stage in individual patient prognosis and determination of treatment is reviewed as well as its value in research and cancer control activities. The conflict between the need for stability of cancer stage definitions over time and the need to evolve with advances in medicine are examined. The ecancer elearning modules on Cancer Stage are introduced.
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/28101140/radiation-induced-breast-angiosarcoma-a-case-report
#2
Sara Tato-Varela, Rosa Albalat-Fernández, Sara Pabón-Fernández, Diego Núñez-García, Manolo La Calle-Marcos
Radiation-induced breast angiosarcoma is a severe but rare late complication in the breast-preserving management of breast cancer through surgery and radiotherapy [1]. Often the initial diagnosis of this entity is complex given its relatively anodyne nature and usually being present in the form of typically multifocal reddish-purple papular skin lesions [2]. Because of the low incidence of this tumour, there is a limited number of studies regarding its optimal therapeutic management [3]. The preferred treatment is aggressive surgical removal and the prognosis is poor with an overall survival rate of 12-20% at five years [4]...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/28101139/solitary-thyroid-metastasis-from-colon-cancer-a-rare-case-report
#3
L Nicosia, S Alessi, M Proh, E Grosso, M Ansarin, A Vingiani, E Pisa, E De Fiori
Malignant metastases to the thyroid are rare and are even rarer from a colorectal primary. As these metastases are often asymptomatic, they are usually discovered incidentally on imaging performed as follow-up for the primary tumour. In this report, we present a case of metastatic sigmoid adenocarcinoma to the thyroid diagnosed and treated at our institution.
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/28101138/research-engagement-among-black-men-with-prostate-cancer
#4
Charlotte Toms, Fidelma Cahill, Gincy George, Mieke Van Hemelrijck
BACKGROUND: Black men are three times more likely to develop prostate cancer (PCa) and often present with more aggressive disease. Nevertheless, black men are consistently underrepresented in research studies. We aimed to get more insight into the reasons for this reduced recruitment, as it is important for future research to include results that are also applicable to black men with PCa. METHODS: Two focus groups (n = 10 and n = 6) of black males currently under treatment for PCa at Guys Hospital, London, UK were held to gather information regarding the understanding of and exposure to research, as well as the barriers and facilitators for recruitment into research studies...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/28101137/validation-of-questionnaire-on-the-spiritual-needs-assessment-for-patients-snap-questionnaire-in-brazilian-portuguese
#5
Diego de Araujo Toloi, Deise Uema, Felipe Matsushita, Paulo Antonio da Silva Andrade, Tiago Pugliese Branco, Fabiana Tomie Becker de Carvalho Chino, Raquel Bezerra Guerra, Túlio Eduardo Flesch Pfiffer, Toshio Chiba, Rodrigo Santa Cruz Guindalini, Daniel P Sulmasy, Rachel P Riechelmann
OBJECTIVES: Spirituality is related to the care and the quality of life of cancer patients. Thus, it is very important to assess their needs. The objective of this study was the translation and cultural adjustment of the Spiritual Needs Assessment for Patients (SNAP) questionnaire to the Brazilian Portuguese language. METHODOLOGY: The translation and cultural adjustment of the SNAP questionnaire involved six stages: backtranslation, revision of backtranslation, translation to the original language and adjustments, pre-test on ten patients, and test and retest with 30 patients after three weeks...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/28101136/hepatic-metastasis-of-thymoma-case-report-and-immunohistochemical-study
#6
Daniela Speisky, María Teresa García de Davila, Felix Vigovich, Julian Mendez, Rafael Maurette, Marcos García Ejarque, Juan Carlos Spina, Alejandro Iotti, Pablo Dezanzo
Thymomas are rare tumours characterised by their slow growth and capacity to invade directly by contiguity. While distant dissemination is infrequent, all sub-types of thymoma have the capacity to metastasise to extrathoracic organs. We present here the case of a female patient with a liver mass discovered 13 years after the removal of a mediastinal thymoma and after ten years from thyroidectomy for papillary carcinoma. The histopathological study showed that the lesion contained an epithelial component, which was immunohistochemically positive for pankeratin...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/28066507/health-technology-assessment-and-value-the-cancer-value-label-cavala-methodology
#7
Francisco Rocha-Gonçalves, Marina Borges, Patrícia Redondo, José Laranja-Pontes
In modern health care systems, the soaring prices of drugs pose at least three major challenges: the growing economic burden of diseases, the uncertainty regarding innovation in health care, and the use of generic drugs and new indications. In this context, the assessment of health care technology is not just about drugs, it is about ensuring that the system's resources, namely financial, yield maximum health benefits. So, the assessment is about relating inputs with outputs; and also, resources with health-related outcomes...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27994649/european-cancer-research-from-bench-to-bedside-and-to-breakfast-table
#8
EDITORIAL
Mursheda Begum, Elena Pallari, Grant Lewison
We examined the outputs, sources of funding, and impact of European cancer research from 2002-13. Outputs were compared with the disease burden and individual countries' wealth. Funding came from a huge number of sources, particularly private-non-profit ones in northern and western Europe. Impacts were determined from citations on cancer clinical guidelines and in European newspaper stories about cancer research.
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27994648/sinonasal-glomangiopericytoma-treated-with-preoperative-embolisation-and-endoscopic-sinus-surgery
#9
Elizabeth Psoma, Petros D Karkos, Stamatia Dova, Michail Gavriilidis, Konstantinos Markou, Constantinos Kouskouras, Afroditi Haritanti, Stefanos Finitsis
Sinonasal glomangiopericytoma is a benign rare tumour of pericytes that accounts for less than 0.5% of all sinonasal tumours. It is an indolent tumour with a macroscopic appearance of common inflammatory polyps. We report the case of a 55-year-old male who presented with right nasal obstruction. CT and MRI examinations demonstrated a soft-tissue mass that obstructed mainly the right nasal cavity. Biopsy revealed glomangiopericytoma. The tumour was treated with preoperative embolisation followed by complete endoscopic resection...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27994647/cancer-immunotherapy-from-the-lab-to-clinical-applications-potential-impact-on-cancer-centres-organisation
#10
Linda Cairns, Sandrine Aspeslagh, Andrea Anichini, Jon Amund Kyte, Christian Blank, Paolo Ascierto, Nicolle Rekers, Per Thor Straten, Ahmad Awada
This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27994646/postoperative-radiotherapy-in-the-management-of-keloids
#11
Claudia C Carvajal, Carla M Ibarra, Douglas L Arbulo, Moisés N Russo, Claudio P Solé
BACKGROUND: The high recurrence rate following keloid resection has generated interest in adjuvant treatments for this disease. OBJECTIVE: This study assesses keloid recurrence when treated with surgery and adjuvant radiotherapy. METHODS: Retrospective analysis of resected keloids in patients referred to a Chilean radiation oncology centre between 2006 and 2013. Local recurrence was defined as new tissue growth on the surgical scar margin...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27994645/next-generation-metronomic-chemotherapy-report-from-the-fifth-biennial-international-metronomic-and-anti-angiogenic-therapy-meeting-6-8-may-2016-mumbai
#12
Pan Pantziarka, Lisa Hutchinson, Nicolas André, Sébastien Benzekry, Francesco Bertolini, Atanu Bhattacharjee, Shubhada Chiplunkar, Dan G Duda, Vikram Gota, Sudeep Gupta, Amit Joshi, Sadhana Kannan, Robert Kerbel, Mark Kieran, Antonella Palazzo, Aparna Parikh, Eddy Pasquier, Vijay Patil, Kumar Prabhash, Yuval Shaked, Giselle Saulnier Sholler, Jaroslav Sterba, David J Waxman, Shripad Banavali
The 5(th) Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6(th) - 8(th) May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27994644/predictors-of-survival-of-natural-killer-t-cell-lymphoma-nasal-type-in-a-non-asian-population-a-single-cancer-centre-experience
#13
Jule Vásquez, Mariana Serrano, Lourdes Lopez, Cristian Pacheco, Shirley Quintana
BACKGROUND: Natural killer/T-cell lymphoma (NKTCL), part of T-cell and NK-cell neoplasms in the World Health Organisation (WHO) classification, is an aggressive lymphoma with poor prognosis more predominantly seen in Asian and South American countries. This study evaluates the factors associated with survival among patients with newly diagnosed NKTCL in Peru. METHODS: Information was abstracted from medical records (MR) for all NKTCL patients >13 years of age at the Instituto Nacional de Enfermedades Neoplasicas (INEN) between 2002 and 2011...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27994643/the-cost-of-cancer-care-is-not-related-to-its-outcomes
#14
Guy Storme, S Dhaese, D Corens, Mark De Ridder
Solid tumours make up 90% of all proliferative diseases and the main action for cure remains surgery, removing the visible tumour as well as the surrounding tissue. Radiotherapy is an added value for eliminating local microscopic as well as regional disease. Systemic treatment has a small impact on the outcome but has a cost, which is as much as all the other actions such as diagnostic tools and treatments.
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27994642/close-cooperation-with-health-technology-assessment-expertise-is-crucial-for-implementation-and-ultimately-reimbursement-of-innovations-in-oncology
#15
W H van Harten, V P Retèl
The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899957/next-generation-sequencing-in-nsclc-and-melanoma-patients-a-cost-and-budget-impact-analysis
#16
Rosa A van Amerongen, Valesca P Retèl, Veerle Mh Coupé, Petra M Nederlof, Maartje J Vogel, Wim H van Harten
Next-generation sequencing (NGS) has reached the molecular diagnostic laboratories. Although the NGS technology aims to improve the effectiveness of therapies by selecting the most promising therapy, concerns are that NGS testing is expensive and that the 'benefits' are not yet in relation to these costs. In this study, we give an estimation of the costs and an institutional and national budget impact of various types of NGS tests in non-small-cell lung cancer (NSCLC) and melanoma patients within The Netherlands...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899956/innovations-that-reach-the-patient-early-health-technology-assessment-and-improving-the-chances-of-coverage-and-implementation
#17
W H van Harten, V P Retèl
With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899955/comparison-between-standard-and-reduced-volume-radiotherapy-in-bladder-preservation-trimodality-protocol-for-muscle-invasive-bladder-cancer-patients
#18
Waleed Arafat, Azza Darwish, George E Naoum, Wael Sameh, Gamal El Husseiny, Fathy Abd-El-Gawad, Mostafa Samir
AIM: Our aim is to compare the toxicity, pelvic nodal relapse, and overall survival of whole bladder irradiation only to the standard technique of whole pelvis irradiation followed by bladder boost in patients with muscle-invasive bladder carcinoma undergoing bladder preservation protocol. MATERIAL AND METHOD: A total of 60 patients with transitional cell carcinoma, stage T2-3, N0, M0 bladder cancer were subjected to maximal transurethral resection bladder tumour (TURB)...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899954/phosphoethanolamine-and-the-danger-of-unproven-drugs
#19
Noam Pondé, Evandro de Azambuja, Felipe Ades
The use of unproven forms of therapy in cancer treatment is very common. In Brazil, the distribution by researchers to patients of an investigational agent called phophoethanolamine (PHOS) has led to a widely publicized scientific scandal. PHOS is a precursor to components of the cell membrane, with some published pre-clinical studies suggesting cytotoxic activity in cancer cells. The willingness of courts and of legislators to guarantee access to PHOS in spite of the lack of any clinical data and against the recommendations of scientific and medical organisations underscores the risks that unproven agents pose to regulatory authorities, health care systems and patients, and bears resemblance to other cases such as the controversy surrounding the approval of zidovudine for AIDS treatment by the FDA...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899953/repurposing-drugs-in-oncology-redo-propranolol-as-an-anti-cancer-agent
#20
Pan Pantziarka, Gauthier Bouche, Vidula Sukhatme, Lydie Meheus, Ilse Rooman, Vikas P Sukhatme
Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response...
2016: Ecancermedicalscience
journal
journal
41838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"